The factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme

Background: Previous randomised controlled trials haveobserved individual differences in response to Glucagon-LikePeptide-1 Receptor Agonists (GLP1RA) according to baselinecharacteristics such as glycated haemoglobin (HbA1c) andweight. The Association of British Clinical Diabetologists (ABCD)launched a nationwide UK audit in January 2019 to assess theclinical utility, efficacy and safety of injectable semaglutide inroutine practice. The aim of this analysis was to investigateassociations between baseline characteristics and HbA1c andweight reductions with semaglutide in real-world use. Methods: Data were extracted from the secure online tool andindividuals who had baseline and follow-up data availablewithin a defined 6 (3-9) month window were included.Variables were assessed as both continuous variables andcategorical variables in a multivariate regression model. Missingdata were multiply imputed. Results: In total, 620 individuals were included. Baselinecharacteristics: (mean±SD) age was 58.7±10.7 years, HbA1c81.6±18.5 mmol/mol (9.5±1.7%), weight 108.2±24.2 kg and bodymass index (BMI) 37.6±7.6 kg/m2. Median diabetes durationwas 11.2 years (IQR 6.6-16) and 50.5% (313/620) of subjectswere male. The median follow-up time was 0.5 years. HbA1creduced by 14.9 mmol/mol (95% CI 13.5, 16.1) [-1.4% (95% CI -1.2, -1.5)]; p<0.001; and weight reduced by 4.2kg (95% CI 3.6,4.8; p<0.001). Higher HbA1c, younger age and GLP1RA naïvetywere associated with larger HbA1c reduction. Higher baselineweight/BMI and GP1RA naïvety were associated with largerweight reduction. Conclusion: In this real-world study, baseline HbA1c and weightwere important predictors of HbA1c and weight reductionoutcomes following initiation of semaglutide in routine clinicalpractice. Our data mirror existing randomised controlled trialdata, but further evidence is being collected over a longerfollow-up period

Citation

Crabtree, T., Adamson, K., Bickerton, A., Evans, A., Phillips, S., Gallagher, A., ... & Ryder, R. E. (2023). The factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme. British Journal of Diabetes, 23(2), 94-100.

DOI

10.15277/bjd.2023.418

URI

https://hdl.handle.net/20.500.14709/537

Usage rights

CC BY 4.0

License

https://creativecommons.org/licenses/by/4.0/